BIDU vs IKT · rev $18.46B vs $215.2M cap
Baidu Inc (BIDU) versus Inhibikase Therapeutics Inc (IKT) — a side-by-side from cached financials, not a winner call.
Baidu Inc (BIDU) is a internet content & information company listed on US.
Inhibikase Therapeutics Inc (IKT) is a biotechnology company listed on US.
Latest reported BIDU revenue for 2025-12-31 was $18.46B. Net income was $799.0M. Revenue was up 1.2% from 2024-12-31 to 2025-12-31. BIDU currently screens at market cap $37.98B.
Latest reported IKT revenue for 2026-06-30 was $0. Net income was -$36.0M. IKT currently screens at market cap $215.2M.
BIDU currently screens at market cap $37.98B. IKT currently screens at market cap $215.2M.
Not investment advice. Open the BIDU and IKT stock pages for the full models.
Not investment advice.